AbbVie, Taro settle over rosacea drug patents

Ab bVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

AbbVie settles longstanding trade secret dispute with Evolus

23 February 2021 AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.

Americas

Health campaigners call for greater checks on AbbVie/Allergan merger

20 February 2020 Trade unions and consumer groups have urged the Federal Trade Commission to intervene in the planned $63 billion merger of drugmakers AbbVie and Allergan, arguing it would “substantially harm competition”.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

AbbVie, Taro settle over rosacea drug patents

More on this story

Editor's picks

Editor's picks

More features